ELRIG Announces Drug Discovery 2015 Programme
News Jun 25, 2015
ELRIG’s Drug Discovery event will feature world class speakers presenting on the latest challenges and advances in early stage and translational drug discovery, and provides scientists an excellent opportunity to network throughout the two days.
As well as the programme of more than 50 scientific presentations, the 2015 event will feature poster sessions, Core Technologies Workshops, SLAS Authors Workshops, an exhibition area with around 100 vendor booths, as well as an Innovation Zone for new and exciting emerging companies and technologies, and a Media Area and Careers Zone.
This year sees the addition of two new scientific sessions, ‘Cell & Gene Therapy’ and ‘New Biologic Drugs & Technologies’, as well as: ‘Innovation in Assay Development & Screening’; ‘Metabolic & Cardiovascular Drug Discovery’; ‘Chemistry Innovation in Lead Discovery’; ‘Target Identification & Validation’; ‘Phenotypic Discovery & Cell Imaging’; and ‘Oncology Drug Targets’.
The Core Technologies Workshops provide a more informal, interactive environment in which to discuss key issues and future directions, coordinated by leaders in their fields. This year the workshops will focus on: ‘Enzymology Applications in Drug Discovery’; ‘Protein:Protein Interaction in Drug Discovery’; ‘Ant-Infectives’; and ‘Future of HTS’.
Plenary keynote speakers at this year’s event are David Thomas, Traffick Therapeutiques, and Professor Tracy Hussell, Manchester Collaborative Centre for Inflammation Research. An interview with Prof. Hussell can be found here. Keynote speakers for the four session tracks include: Stephen Rees, AstraZeneca; Dr Chris Torrance, PhoreMost Ltd; Gerard Drewes, Cellzome; Stefano Pluchino , Wellcome Trust-MRC Stem Cell Institute, University of Cambridge (UK); Chas Bountra, SGC, University of Oxford; Philipp Holliger , MRC Laboratory of Molecular Biology; Damian Young, Baylor College of Medicine; and Daniel P. Kelly, Sanford-Burnham Medical Research Institute at Lake Nona.
Cellular Valve Structure Opens Up Potential Novel TherapiesNews
Biochemists have determined the detailed structure of a volume-regulated chloride channel. This cellular valve is activated in response to swelling to prevent the cell from bursting. The protein also plays an important role in the uptake of chemotherapeutics and the release of neurotransmitters after a stroke. The controlled regulation of its activity thus opens up a promising strategy for novel therapies.READ MORE
Computation and Chemistry Combine to Create World-First Auxetic ProteinNews
A team of chemists at the University of California, San Diego (UCSD) has now designed a two-dimensional protein crystal that toggles between states of varying porosity and density. This is a first in biomolecular design that combined experimental studies with computation done on supercomputers. The research, published in April 2018 in Nature Chemistry, could help create new materials for renewable energy, medicine, water purification, and more.
Fructose Formula Poses Risk to Babies With Metabolic DisorderNews
Babies with inherited intolerance of fructose face a risk of acute liver failure if they are fed certain widely available formulas containing fructose, pediatricians and geneticists are warning. Baby formula manufacturers should remove fructose or sucrose, or explicitly label their products to allow parents to avoid those sweeteners if necessary, the doctors say.